These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27587319)

  • 1. Comparative Analysis of Persistence to Treatment among Patients with Asthma or COPD Receiving AirFluSal Forspiro or Seretide Diskus Salmeterol/Fluticasone Propionate Combination Therapy.
    Bender BG; Hernandez Vecino RA; McGrath K; Jones S
    J Allergy Clin Immunol Pract; 2016; 4(5):884-9. PubMed ID: 27587319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial.
    Jõgi R; Lähelmä S; Vahteristo M; Happonen A; Haikarainen J
    J Aerosol Med Pulm Drug Deliv; 2019 Apr; 32(2):88-98. PubMed ID: 30300557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers.
    Chapman KR; Ringdal N; Backer V; Palmqvist M; Saarelainen S; Briggs M
    Can Respir J; 1999; 6(1):45-51. PubMed ID: 10202220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a Therapeutic Interchange from Fluticasone/Salmeterol to Mometasone/Formoterol in Patients with Chronic Obstructive Pulmonary Disease.
    Yip E; Karimi S; Pien LT
    J Manag Care Spec Pharm; 2016 Apr; 22(4):316-23. PubMed ID: 27023685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients.
    Ismaila A; Corriveau D; Vaillancourt J; Parsons D; Dalal A; Su Z; Sampalis JS
    Curr Med Res Opin; 2014 Jul; 30(7):1427-36. PubMed ID: 24666181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler versus a multi-dose inhaler in patients with chronic obstructive pulmonary disease.
    Chan R; Sousa AR; Hynds P; Homayoun-Valiani F; Edwards D; Tabberer M
    Pulm Pharmacol Ther; 2017 Apr; 43():12-19. PubMed ID: 28115223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.
    Jones R; Martin J; Thomas V; Skinner D; Marshall J; Stagno d'Alcontres M; Price D
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2445-2454. PubMed ID: 28860739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma.
    Ng D; Kerwin EM; White MV; Miller SD; Haughie S; Ward JK; Allan R
    J Aerosol Med Pulm Drug Deliv; 2020 Apr; 33(2):99-107. PubMed ID: 31634023
    [No Abstract]   [Full Text] [Related]  

  • 10. Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler in patients with asthma.
    Chan R; Sousa AR; Mallett S; Hynds P; Homayoun-Valiani F; Tabberer M; Mehta R
    Pulm Pharmacol Ther; 2016 Dec; 41():19-24. PubMed ID: 27599598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 6-month safety and efficacy study of fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers in persistent asthma.
    Mansfield L; Yiu G; Sakov A; Liu S; Caracta C
    Allergy Asthma Proc; 2017 Jul; 38(4):264-276. PubMed ID: 28540844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Pharmacokinetics of Salmeterol and Fluticasone Propionate 50/100 µg Delivered in Combination as a Dry Powder Via a Capsule-Based Inhaler and a Multi-Dose Inhaler.
    Mehta R; Riddell K; Gupta A; Louey MD; Chan RH
    Clin Drug Investig; 2015 May; 35(5):319-26. PubMed ID: 25805608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
    Murray J; Rosenthal R; Somerville L; Blake K; House K; Baitinger L; VanderMeer A; Dorinsky P
    Ann Allergy Asthma Immunol; 2004 Oct; 93(4):351-9. PubMed ID: 15521371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluticasone Propionate/Salmeterol MDPI (AirDuo RespiClick
    Paik J; Scott LJ; Pleasants RA
    Clin Drug Investig; 2018 May; 38(5):463-473. PubMed ID: 29582249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler.
    Mehta R; Daley-Yates PT; Jenkins K; Bianco J; Stylianou A; Louey MD; Chan RH
    Pulm Pharmacol Ther; 2014 Oct; 29(1):66-73. PubMed ID: 25035069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device.
    Tashkin DP; Ohar JA; Koltun A; Allan R; Ward JK
    Pulm Med; 2021; 2021():8881895. PubMed ID: 33815843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and economic outcomes associated with the use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium bromide 18 mcg as initial maintenance treatment for chronic obstructive pulmonary disease in managed care.
    Bell CF; Coutinho AD; Farrelly E; Lokhandwala T; Landsman-Blumberg P
    J Med Econ; 2018 Jun; 21(6):629-638. PubMed ID: 29577787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease.
    Feldman WB; Kesselheim AS; Avorn J; Russo M; Wang SV
    Ann Intern Med; 2023 Aug; 176(8):1047-1056. PubMed ID: 37549393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD.
    Gao J; Pleasants RA
    Int J Chron Obstruct Pulmon Dis; 2015; 10():775-89. PubMed ID: 25926729
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Shepherd T; Kennett M; Cooper A; Parkinson A
    J Aerosol Med Pulm Drug Deliv; 2022 Jun; 35(3):154-165. PubMed ID: 34726509
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.